Human Umbilical Vein Endothelial Cells (HUVEC) Market
Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis By Type (Single Donors, Pooled Donors), By Application (Wound Healing, Angiogenesis, Oncology, Tissue Engineering), By Region - Global Insights 2021 to 2031
Analysis of Human Umbilical Vein Endothelial Cells (HUVEC) market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Key Questions Answered in Report
-
Which is the most promising application area for human umbilical vein endothelial cells (HUVEC)?
According to Fact.MR, the oncology segment is anticipated to accrue highly lucrative gains to the human umbilical vein endothelial cells (HUVEC) market, attributed to their purported effectiveness in targeting malignant growth. Simultaneously, uptake across tissue culture is also likely to widen in the future.
-
Which countries are likely to offering promising expansion prospects for HUVEC through 2031?
The U.S. and Indian markets are expected to provide immense growth opportunities for HUVEC, as both countries are making significant strides in furthering good quality healthcare across key domains as CVD and cancer treatment.
-
Which prominent players are operating within the global HUVEC landscape?
Some of the prominent players involved in human umbilical vein epithelial cells include Lonza Group AG, PromoCell- Human Centered Science, Merck & Co. KGaA, Thermo Fisher Scientific, Lifeline, and Corning Inc.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Human Umbilical Vein Endothelial Cells 2016 to 2020 Trends Vs Projections for 2021 to 2031
From 2016 to 2020, demand for human umbilical vein endothelial cell-based treatment has been gradually gaining momentum, as advancements in genetic engineering and biotechnology become increasingly overt. Extensive applications are being witnessed in the oncology domain, followed by tissue culture and angiogenesis.
Growth of the market remained consistent across the COVID-19 pandemic, although initial shocks were experienced in the first half of 2020, attributed to reduced hospital visits amid fears of contracting the novel coronavirus infection. Future prospects are extremely lucrative, especially across emerging economies across Asia as spending on healthcare infrastructure augments.
How is Surging Tissue Engineering Popularity Augmenting Adoption of Human Umbilical Vein Endothelial Cells?
Over the years, tissue engineering has acquired immense popularity, being deployed across a broad spectrum of treatment domains. Tissue engineering provides alternatives to surgical reconstruction, transplants, and other mechanical devices that are used to repair damaged tissues.
The market for tissue engineering is also driven by a continuous increase in the need for effective regenerative treatments owing to a rise in the prevalence of diabetes, obesity, and other disorders due to lifestyle changes, aging population, and growing trauma cases. Hence, demand for human umbilical vein endothelial cells based treatment is garnering significant momentum.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What is the Scope of HUVEC in Angiogenesis?
Angiogenesis using human umbilical vein endothelial cells is proving highly beneficial to address hepatocellular carcinoma (HCC), a typical hyper-vascular tumour. Hepatocellular carcinoma is a debilitating form of liver cancer which typically arises post a severe Hepatitis B or C infection.
Hence, prominent healthcare providers are leveraging advanced treatment and diagnosis approaches to address this condition. Hepatocellular carcinoma is an aggressive malignancy, resulting as the third cause of death by cancer each year. The management of patients with HCC is complex, as both the tumour stage and any underlying liver disease must be considered conjointly.
Country-wise Analysis
How Bright are HUVEC Growth Prospects across the U.S.?
HUVEC-based treatment adoption rate in the U.S. is expanding rapidly to treat cardiovascular diseases. Several studies have established that HUVECs are a highly useful model for research on human endothelium, and is effective in examining the pathophysiological mechanisms involved in the onset of CVDs.
Additionally, this approach is being increasingly incorporated in the diagnosis and treatment of various forms of cancers. Furthermore, these cells are also being incorporated in angiogenesis to study ovulation, inflammation and tumour growth patterns.
Why is India Considered a Lucrative Market for HUVEC Players?
In recent years, India has generated a fertile space for cell culture- and tissue culture-based treatment. As biotechnology acquires rapid pace in the country, numerous initiatives are being undertaken to further its applications across the broad spectrum of treatment areas.
As per data published by India Against Cancer, around 2.25 million people are afflicted with the disease, with new patients amounting to over a million every year. Hence, major companies are accelerating efforts to discover potent treatments, elevating prospects for HUVEC based treatment.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
How are Pooled Donor HUVECs Generating Demand?
By type, pooled donor HUVECs are acquiring significant popularity, and the segment is projected to expand at more than 10% CAGR through 2031, attributed to their ability to reduce donor variability so as to provide a uniform and consistent application standard to key genetic research platforms.
Players such as Lonza offer a series of cryopreserved HUVECs, shipped as frozen primaries, which are pooled donor and single donor based. Their XL size consists of 10 million cells/ampoule which are achieved by pooling donors.
Which is the Primary Application Area of HUVECs?
HUVECs for oncology and cancer treatment are expected to find immense applications over the decade, with the segment expected to surge ahead at 12%-15% CAGR, as prominent healthcare settings leverage the latest cell technology to eradicate the disease.
For instance, HUVEC-docetaxel (DOC) treatment has been proven to make significant breakthroughs with respect to breast cancer treatment, exhibiting more favourable anti-EMT-6 breast cancer effects in vivo.
Competitive Landscape
The HUVEC landscape appears highly consolidated, marked by the presence of a handful of service providers across prominent geographies. These players primarily concentrate on offering high-grade product offerings as their primary expansion strategy.
- In December 2020, Corning Inc. launched the Corning® X-SERIES® cell processing platform which delivers fast, sterile, automated and efficient processing of human blood and blood products to obtain purified populations of immune cells for gene therapy applications
- Thermo Fisher Scientific offers the GibcoTM HUVEC Adherent Cell Culture which is cryopreserved and tested for Hepatitis B (HBV), Hepatitis C (HCV), sterility testing (bacterial & fungi), mycoplasma, HIV-1 and as a growth performance assay
*This list is indicative- full details about prominent human umbilical endothelial cells providers is available upon request.
Report Scope
|
Attribute |
Details |
|
Forecast Period |
2021-2031 |
|
Historical Data Available for |
2016-2020 |
|
Market Analysis |
US$ Mn for Value & ‘000 Units for Volume |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Segments Covered |
|
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Market Segments Covered
-
Type
- Single Donors of Human Umbilical Vein Endothelial Cells
- Pooled Donors of Human Umbilical Vein Endothelial Cells
-
Application
- Human Umbilical Vein Endothelial Cells for Wound Healing
- Human Umbilical Vein Endothelial Cells for Angiogenesis
- Human Umbilical Vein Endothelial Cells for Tissue Engineering
- Human Umbilical Vein Endothelial Cells for Inflammation Treatment
- Human Umbilical Vein Endothelial Cells for Oncology
- Human Umbilical Vein Endothelial Cells for Other Applications
-
Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K
- Italy
- Russia
- Nordics
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Rest of Asia Pacific
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- GCC
- Turkey
- Rest of MEA
- North America
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions/Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product modifications /Innovation 4. Key Success Factors 4.1. Strategic Developments 4.2. Key regulations 4.3. Product USPs /Technology 4.4. List of manufacturers and providers 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP outlook 5.1.2. Increasing R&D Expenditure 5.2. Forecast Factors - Relevance & Impact 5.2.1. New product launches 5.2.2. Cost of products 5.2.3. Increasing adoption of Human Umbilical Vein Endothelial Cells (HUVEC) 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID19 Crisis Analysis 6.1.1. Current COVID19 Statistics and Probable Future Impact 6.1.2. Current GDP Projection and Probable Impact 6.1.3. Current Economic Projection as compared to 2008 Economic analysis 6.1.4. COVID19 and Impact Analysis 6.1.4.1. Revenue By Type 6.1.4.2. Revenue By Application 6.1.4.3. Revenue By Country 6.1.5. 2020 Market Scenario 6.1.6. Quarter by Quarter Forecast 6.1.7. Projected Recovery Quarter 7. Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Volume (Units) Analysis 2016-2020 and Forecast, 2021-2031 7.1. Historical Market Volume (Units) Analysis, 2016-2020 7.2. Current and Future Market Volume (Units) Projections, 2021-2031 7.2.1. Y-o-Y Growth Trend Analysis 8. Global Human Umbilical Vein Endothelial Cells (HUVEC) Market - Pricing Analysis 8.1. Regional Pricing Analysis By Type 8.2. Pricing Break-up 8.2.1. Manufacturer Level Pricing 8.2.2. Distributor Level Pricing 8.3. Global Average Pricing Analysis Benchmark 9. Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis 2016–2020 and Forecast, 2021-2031 9.1. Historical Market Value (US$ Mn) Analysis, 2016–2020 9.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031 9.2.1. Y-o-Y Growth Trend Analysis 9.2.2. Absolute $ Opportunity Analysis 10. Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 2016–2020 and Forecast 2021-2031, by Type 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Products & Services, 2016–2020 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Type, 2021-2031 10.3.1. Single Donors 10.3.2. Pooled Donors 10.4. Market Attractiveness Analysis By Type 11. Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 2016–2020 and Forecast 2021-2031, by Application 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By Application , 2016–2020 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application , 2021-2031 11.3.1. Wound Healing 11.3.2. Angiogenesis 11.3.3. Tissue Engineering 11.3.4. Inflammation 11.3.5. Oncology 11.3.6. Others 11.4. Market Attractiveness Analysis By Application 12. Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 2016–2020 and Forecast 2021-2031, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2016–2020 12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2031 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 2016–2020 and Forecast 2021-2031 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016–2020 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Type 13.3.3. By Application 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Latin America Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 2016–2020 and Forecast 2021-2031 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016–2020 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Type 14.3.3. By Application 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. Europe Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 2016–2020 and Forecast 2021-2031 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016–2020 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. Russia 15.3.1.7. Rest of Europe 15.3.2. By Type 15.3.3. By Application 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. South Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 2016–2020 and Forecast 2021-2031 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016–2020 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Rest of South Asia 16.3.2. By Type 16.3.3. By Application 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. East Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 2016–2020 and Forecast 2021-2031 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016–2020 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.1.4. Rest of East Asia 17.3.2. By Type 17.3.3. By Application 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Oceania Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 2016–2020 and Forecast 2021-2031 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016–2020 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Type 18.3.3. By Application 18.4. Market Attractiveness Analysis 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 19. Middle East and Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 2016–2020 and Forecast 2021-2031 19.1. Introduction 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016–2020 19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. South Africa 19.3.1.3. Rest of Middle East and Africa 19.3.2. By Type 19.3.3. By Application 19.4. Market Attractiveness Analysis 19.5. Drivers and Restraints - Impact Analysis 20. Key and Emerging Countries Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 2016–2020 and Forecast 2021-2031 20.1. Introduction 20.1.1. Market Value Proportion Analysis, By Key Countries 20.1.2. Global Vs. Country Growth Comparison 20.2. U.S. Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.2.1. By Type 20.2.2. By Application 20.3. Canada Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.3.1. By Type 20.3.2. By Application 20.4. Mexico Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.4.1. By Type 20.4.2. By Application 20.5. Brazil Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.5.1. By Type 20.5.2. By Application 20.6. U.K. Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.6.1. By Type 20.6.2. By Application 20.7. Germany Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.7.1. By Type 20.7.2. By Application 20.8. France Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.8.1. By Type 20.8.2. By Application 20.9. Italy Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.9.1. By Type 20.9.2. By Application 20.10. Spain Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.10.1. By Type 20.10.2. By Application 20.11. BENELUX Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.11.1. By Type 20.11.2. By Application 20.12. Russia Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.12.1. By Type 20.12.2. By Application 20.13. China Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.13.1. By Type 20.13.2. By Application 20.14. Japan Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.14.1. By Type 20.14.2. By Application 20.15. South Korea Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.15.1. By Type 20.15.2. By Application 20.16. India Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.16.1. By Type 20.16.2. By Application 20.17. ASEAN Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.17.1. By Type 20.17.2. By Application 20.18. Australia Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.18.1. By Type 20.18.2. By Application 20.19. New Zealand Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.19.1. By Type 20.19.2. By Application 20.20. GCC Countries Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.20.1. By Type 20.20.2. By Application 20.21. Turkey Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.21.1. By Type 20.21.2. By Application 20.22. South Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis 20.22.1. By Type 20.22.2. By Application 21. Market Structure Analysis 21.1. Market Analysis by Tier of Companies 21.2. Market Concentration 21.3. Market Share Analysis of Top Players 21.4. Market Presence Analysis 21.4.1. By Regional footprint of Players 21.4.2. Product foot print by Players 21.4.3. Channel Foot Print by Players 22. Competition Analysis 22.1. Competition Dashboard 22.2. Competition Benchmarking 22.3. Competition Deep dive 22.3.1. Lonza Group AG 22.3.1.1. Overview 22.3.1.2. Product Portfolio 22.3.1.3. Profitability by Market Segments (Product/Channel/Region) 22.3.1.4. Sales Footprint 22.3.1.5. Strategy Overview 22.3.1.5.1. Marketing Strategy 22.3.1.5.2. Product Strategy 22.3.1.5.3. Channel Strategy 22.3.2. PromoCell- Human Centered Science 22.3.2.1. Overview 22.3.2.2. Product Portfolio 22.3.2.3. Profitability by Market Segments (Product/Channel/Region) 22.3.2.4. Sales Footprint 22.3.2.5. Strategy Overview 22.3.2.5.1. Marketing Strategy 22.3.2.5.2. Product Strategy 22.3.2.5.3. Channel Strategy 22.3.3. Merck & Co. KGaA 22.3.3.1. Overview 22.3.3.2. Product Portfolio 22.3.3.3. Profitability by Market Segments (Product/Channel/Region) 22.3.3.4. Sales Footprint 22.3.3.5. Strategy Overview 22.3.3.5.1. Marketing Strategy 22.3.3.5.2. Product Strategy 22.3.3.5.3. Channel Strategy 22.3.4. Thermo Fisher Scientific 22.3.4.1. Overview 22.3.4.2. Product Portfolio 22.3.4.3. Profitability by Market Segments (Product/Channel/Region) 22.3.4.4. Sales Footprint 22.3.4.5. Strategy Overview 22.3.4.5.1. Marketing Strategy 22.3.4.5.2. Product Strategy 22.3.4.5.3. Channel Strategy 22.3.5. Lifeline 22.3.5.1. Overview 22.3.5.2. Product Portfolio 22.3.5.3. Profitability by Market Segments (Product/Channel/Region) 22.3.5.4. Sales Footprint 22.3.5.5. Strategy Overview 22.3.5.5.1. Marketing Strategy 22.3.5.5.2. Product Strategy 22.3.5.5.3. Channel Strategy 22.3.6. Corning Inc. 22.3.6.1. Overview 22.3.6.2. Product Portfolio 22.3.6.3. Profitability by Market Segments (Product/Channel/Region) 22.3.6.4. Sales Footprint 22.3.6.5. Strategy Overview 22.3.6.5.1. Marketing Strategy 22.3.6.5.2. Product Strategy 22.3.6.5.3. Channel Strategy 23. Assumptions and Acronyms Used 24. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Volume (‘000 Units) Analysis and Opportunity Assessment 2016–2031, By Type
Table 02: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Type
Table 03: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Application
Table 04: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Region
Table 05: North America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 06: North America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Type
Table 07: North America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Application
Table 08: Latin America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 09: Latin America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Type
Table 10: Latin America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Application
Table 11: Europe Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 12: Europe Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Type
Table 13: Europe Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Application
Table 14: South Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 15: South Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Type
Table 16: South Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Application
Table 17: East Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 18: East Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Type
Table 19: East Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Application
Table 20: Oceania Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 21: Oceania Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Type
Table 22: Oceania Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Application
Table 23: Middle East and Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 24: Middle East and Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Type
Table 25: Middle East and Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Application
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Volume (in 000' Units) Analysis, 2016-2020
Figure 02: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Volume Forecast (in 000' Units), 2021-2031
Figure 03: Human Umbilical Vein Endothelial Cells (HUVEC) Pricing Analysis (US$) Per Product, By Region, 2020
Figure 04: Human Umbilical Vein Endothelial Cells (HUVEC) Pricing Analysis (US$) Per Product, By Region, 2020
Figure 05: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2016-2020
Figure 06: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Forecast (US$ Mn), 2021-2031
Figure 07: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Absolute $ Opportunity, 2021-2031
Figure 08: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Share Analysis (%), By Type, 2021-2031
Figure 09: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Y-o-Y Analysis (%), By Type, 2021-2031
Figure 10: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Type, 2021-2031
Figure 11: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Share Analysis (%), By Application, 2021-2031
Figure 12: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Y-o-Y Analysis (%), By Application, 2021-2031
Figure 13: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Application, 2021-2031
Figure 14: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Share Analysis (%), By Region, 2021-2031
Figure 15: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Y-o-Y Analysis (%), By Region, 2021-2031
Figure 16: Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Region, 2021-2031
Figure 17: North America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 18: North America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 19: North America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Country, 2021 (E)
Figure 20: North America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2016-2020
Figure 21: North America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Forecast (US$ Mn), 2021-2031
Figure 22: North America Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Type, 2021-2031
Figure 23: North America Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Application, 2021-2031
Figure 24: North America Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Country, 2021-2031
Figure 25: Latin America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 26: Latin America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 27: Latin America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Country, 2021 (E)
Figure 28: Latin America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2016-2020
Figure 29: Latin America Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Forecast (US$ Mn), 2021-2031
Figure 30: Latin America Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Type, 2021-2031
Figure 31: Latin America Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Application, 2021-2031
Figure 32: Latin America Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Country, 2021-2031
Figure 33: Europe Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 34: Europe Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 35: Europe Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Country, 2021 (E)
Figure 36: Europe Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2016-2020
Figure 37: Europe Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Forecast (US$ Mn), 2021-2031
Figure 38: Europe Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Type, 2021-2031
Figure 39: Europe Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Application, 2021-2031
Figure 40: Europe Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Country, 2021-2031
Figure 41: South Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 42: South Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 43: South Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Country, 2021 (E)
Figure 44: South Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2016-2020
Figure 45: South Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Forecast (US$ Mn), 2021-2031
Figure 46: South Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Type, 2021-2031
Figure 47: South Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Application, 2021-2031
Figure 48: South Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Country, 2021-2031
Figure 49: East Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 50: East Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 51: East Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Country, 2021 (E)
Figure 52: East Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2016-2020
Figure 53: East Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Forecast (US$ Mn), 2021-2031
Figure 54: East Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Type, 2021-2031
Figure 55: East Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Application, 2021-2031
Figure 56: East Asia Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Country, 2021-2031
Figure 57: Oceania Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 58: Oceania Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 59: Oceania Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Country, 2021 (E)
Figure 60: Oceania Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2016-2020
Figure 61: Oceania Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Forecast (US$ Mn), 2021-2031
Figure 62: Oceania Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Type, 2021-2031
Figure 63: Oceania Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Application, 2021-2031
Figure 64: Oceania Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Country, 2021-2031
Figure 65: Middle East and Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 66: Middle East and Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 67: Middle East and Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Country, 2021 (E)
Figure 68: Middle East and Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2016-2020
Figure 69: Middle East and Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Forecast (US$ Mn), 2021-2031
Figure 70: Middle East and Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Type, 2021-2031
Figure 71: Middle East and Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Application, 2021-2031
Figure 72: Middle East and Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Attractiveness Analysis by Country, 2021-2031
Figure 73: U. S. Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 74: U. S. Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 75: U. S. Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 76: Canada Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 77: Canada Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 78: Canada Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 79: Mexico Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 80: Mexico Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 81: Mexico Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 82: Brazil Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 83: Brazil Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 84: Brazil Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 85: U. K. Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 86: U. K. Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 87: U. K. Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 88: Germany Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 89: Germany Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 90: Germany Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 91: France Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 92: France Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 93: France Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 94: Italy Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 95: Italy Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 96: Italy Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 97: Spain Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 98: Spain Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 99: Spain Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 100: Russia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 101: Russia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 102: Russia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 103: China Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 104: China Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 105: China Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 106: Japan Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 107: Japan Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 108: Japan Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 109: South Korea Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 110: South Korea Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 111: South Korea Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 112: India Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 113: India Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 114: India Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 115: ASEAN Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 116: ASEAN Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 117: ASEAN Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 118: Australia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 119: Australia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 120: Australia Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 121: New Zealand Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 122: New Zealand Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 123: New Zealand Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 124: GCC Countries Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 125: GCC Countries Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 126: GCC Countries Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 127: Turkey Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 128: Turkey Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 129: Turkey Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Figure 130: South Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Analysis (US$ Mn), 2021 & 2031
Figure 131: South Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Type, 2021 (E)
Figure 132: South Africa Human Umbilical Vein Endothelial Cells (HUVEC) Market Value Share, By Application, 2021 (E)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How fast is the human umbilical vein endothelial cells (HUVEC) market projected to expand from 2021 to 2031?
According to Fact.MR, the human umbilical vein endothelial cells market is projected to surge ahead at approx. 10% CAGR through 2031, with the growth rate even higher in Western countries as compared to other parts of the world.
Which is the most promising application area for human umbilical vein endothelial cells (HUVEC)?
The oncology segment is anticipated to accrue highly lucrative gains to the human umbilical vein endothelial cells (HUVEC) market, expanding at close to 15% CAGR over the next ten years, attributed to their purported effectiveness in targeting malignant g
Which countries are likely to offering promising expansion prospects for HUVEC through 2031?
North America, especially the U.S., and Europe, are expected to account for more than 40% market share, and are expected to provide immense growth opportunities for HUVEC, as both regions are making significant strides in furthering good quality healthcar
Which prominent players are operating within the global HUVEC landscape?
Some of the prominent players involved in human umbilical vein epithelial cells include Lonza Group AG, PromoCell- Human Centered Science, Merck & Co. KGaA, Thermo Fisher Scientific, Lifeline, and Corning Inc.
Human Umbilical Vein Endothelial Cells (HUVEC) Market